Demetris D. Crum - 18 Feb 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: EVP, CHIEF HR OFFICER
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum
Issuer symbol: ABBV
Transactions as of: 18 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 20 Feb 2026, 18:35:14 UTC
Previous filing: 30 Jul 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Crum Demetris D	EVP, CHIEF HR OFFICER	1 N. WAUKEGAN ROAD, NORTH CHICAGO	/s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum	20 Feb 2026	0002078592

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+1,216	+17%	$0.000000	8,264	18 Feb 2026	Direct	F1
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+1,244	+15%	$0.000000	9,508	18 Feb 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Option (Right to buy)	Award	$0	+13,406		$0.000000	13,406	18 Feb 2026	Common Stock	13,406	$230.04	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F2	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F3	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029.